These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 19789217)

  • 61. The differential anti-tumour effects of zoledronic acid in breast cancer - evidence for a role of the activin signaling pathway.
    Wilson C; Ottewell P; Coleman RE; Holen I
    BMC Cancer; 2015 Feb; 15():55. PubMed ID: 25884855
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Anticancer activity of bisphosphonates in breast cancer.
    Gnant M
    Anticancer Agents Med Chem; 2012 Feb; 12(2):114-22. PubMed ID: 21864231
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature.
    Gnant M; Clézardin P
    Cancer Treat Rev; 2012 Aug; 38(5):407-15. PubMed ID: 21983264
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Wenshen Zhuanggu formula effectively suppresses breast cancer bone metastases in a mouse Xenograft model.
    Li JJ; Chen WL; Wang JY; Hu QW; Sun ZP; Zhang S; Liu S; Han XH
    Acta Pharmacol Sin; 2017 Oct; 38(10):1369-1380. PubMed ID: 28414206
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model.
    Qiao H; Wang TY; Yu ZF; Han XG; Liu XQ; Wang YG; Fan QM; Qin A; Tang TT
    Cell Death Dis; 2016 Feb; 7(2):e2094. PubMed ID: 26866274
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
    Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
    Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The anti-tumor potential of zoledronic acid.
    Croucher P; Jagdev S; Coleman R
    Breast; 2003 Aug; 12 Suppl 2():S30-6. PubMed ID: 14659141
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro.
    Gschwantler-Kaulich D; Weingartshofer S; Grunt TW; Mairhofer M; Tan Y; Gamper J; Singer CF
    PLoS One; 2017; 12(9):e0185566. PubMed ID: 28945801
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Zoledronic acid in the treatment of metastatic breast cancer.
    Lluch A; Cueva J; Ruiz-Borrego M; Ponce J; Pérez-Fidalgo JA
    Anticancer Drugs; 2014 Jan; 25(1):1-7. PubMed ID: 24100278
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
    J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.
    Guenther A; Gordon S; Tiemann M; Burger R; Bakker F; Green JR; Baum W; Roelofs AJ; Rogers MJ; Gramatzki M
    Int J Cancer; 2010 Jan; 126(1):239-46. PubMed ID: 19621390
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Anticancer properties of zoledronic acid.
    Green J; Lipton A
    Cancer Invest; 2010 Nov; 28(9):944-57. PubMed ID: 20879838
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Vitamin D deficiency promotes growth of MCF-7 human breast cancer in a rodent model of osteosclerotic bone metastasis.
    Ooi LL; Zheng Y; Zhou H; Trivedi T; Conigrave AD; Seibel MJ; Dunstan CR
    Bone; 2010 Oct; 47(4):795-803. PubMed ID: 20638491
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice.
    Ottewell PD; Brown HK; Jones M; Rogers TL; Cross SS; Brown NJ; Coleman RE; Holen I
    Breast Cancer Res Treat; 2012 Jun; 133(2):523-36. PubMed ID: 21956211
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in vivo.
    Jia X; Cheng J; Shen Z; Shao Z; Liu G
    Mol Med Rep; 2018 Apr; 17(4):5470-5476. PubMed ID: 29393454
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
    Hiraga T; Williams PJ; Ueda A; Tamura D; Yoneda T
    Clin Cancer Res; 2004 Jul; 10(13):4559-67. PubMed ID: 15240548
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients.
    Vincenzi B; Santini D; Dicuonzo G; Battistoni F; Gavasci M; La Cesa A; Grilli C; Virzì V; Gasparro S; Rocci L; Tonini G
    J Interferon Cytokine Res; 2005 Mar; 25(3):144-51. PubMed ID: 15767788
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
    Harvey HA
    Semin Oncol; 2004 Dec; 31(6 Suppl 12):23-30. PubMed ID: 15719598
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Characterization of the attenuation of breast cancer bone metastasis in mice by zoledronic acid using (99m)Tc bone scintigraphy.
    Wu C; Yang S; Sun Z; Han X; Ye Y; Liu S
    Pathol Oncol Res; 2014 Jul; 20(3):747-54. PubMed ID: 24610002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.